A recent clinical trial has demonstrated that the novel peptide formulation OS-01 EYE effectively reduces signs of periorbital skin aging, offering improvements in hydration, firmness, elasticity, and the reduction of fine lines, puffiness, and dark circles. Results from both short- and long-term use showed significant skin enhancements after 4 and 12 weeks of treatment.
The study involved 22 participants, aged 47 to 65, with 16 women and 6 men. All participants had a Fitzpatrick skin type between I and III. The treatment regimen consisted of applying a dime-sized amount of OS-01 EYE twice daily, along with a standardized skincare routine that included cleanser, moisturizer, and sunscreen to control for variability.
The serum contains a high concentration of senomorphic peptide OS-01, which promotes DNA repair and reduces skin DNA methylation age. It is further enhanced with active ingredients such as acetyl hexapeptide-8, Fucus vesiculosus extract, Moringa oleifera seed extract, and hyaluronic acid to stimulate collagen production and provide enhanced moisturization.
Skin assessments were conducted at baseline, 4 weeks, and 12 weeks. Researchers employed both bioinstrumental methods and patient-reported questionnaires to measure hydration, barrier function, skin firmness, and elasticity. Visual assessments using VISIA-CR imaging analyzed fine lines, wrinkles, puffiness, and dark circles. Results were confirmed through post-hoc statistical analysis.
The clinical outcomes were overwhelmingly positive. Transepidermal water loss (TEWL) decreased by 10.07% at week 4 and 17.33% by week 12. Skin hydration increased by 20.37% at week 4 and 32.49% by week 12, with both results statistically significant (p < 0.001). Additionally, skin firmness improved by 6.29% at week 4 and 10.19% at week 12, while skin elasticity increased by 13.75% at week 4 and 25.58% at week 12.
In terms of visible improvements, 45.45% of patients experienced a reduction in fine lines and wrinkles by week 4, improving to a mean of 6.87% by week 12. Puffiness was reduced in half of the participants by week 4, with further improvement to a mean of 10.90% by week 12 (p < 0.001). Dark circles showed no change at week 4, but 50% of patients reported a significant improvement by week 12 (p < 0.001).
The overall appearance of participants showed substantial improvement, with 95.46% of patients noting positive changes, particularly in hydration, firmness, elasticity, and skin radiance. While some parameters showed a slight decrease at week 12, researchers suggest that these changes may be attributed to the fact that visible improvements were already prominent by week 4.
VISIA-CR imaging, which graded wrinkles, smoothness, and puffiness, confirmed the clinical findings, with nearly half of the participants showing improvements. Importantly, no adverse events were reported, and none of the participants discontinued the product.
The OS-01 peptide has already been proven safe in previous studies, both in vivo and ex vivo, in a double-blind, split-face clinical trial.
Researchers noted that the periorbital area, due to its thinner skin, tends to show signs of aging more rapidly compared to other facial regions. This makes the need for specialized treatments more pressing. The OS-01 EYE serum addresses this concern with its powerful and safe formulation.
“This study provides compelling evidence for using the OS-01 peptide-containing formulation as a pro-longevity treatment for periorbital skin,” the researchers concluded.
Related topics
